Sherry Aulin is the Chief Financial Officer at Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for epilepsy and other neurological disorders. Appointed in 2021, Sherry leads the company's global finance organization, overseeing financial planning, reporting, investor relations, treasury, tax, and capital markets strategies. Her leadership has been instrumental in securing substantial financing to advance Xenon's pipeline, including the pivotal Phase 3 development of its lead candidate, azetukalner, a potential first-in-class KV7 potassium channel opener for treatment-resistant epilepsy. With more than 25 years of experience in the life sciences sector, Sherry previously served as CFO at Zymeworks Inc., where she orchestrated the company's landmark Nasdaq debut in 2019 and raised over $1.2 billion through public offerings and partnerships, fueling its expansion into oncology therapeutics. Earlier, as Vice President of Finance at Aurinia Pharmaceuticals Inc., she contributed to its Nasdaq listing and growth in autoimmune disease treatments. Sherry's career also includes senior finance roles at Cardiome Pharma Corp. and began at KPMG LLP, where she earned her Chartered Professional Accountant designation. Sherry's achievements include guiding multiple biotech firms through IPOs, mergers, and financings amid volatile markets, earning recognition for her strategic foresight and operational excellence. At Xenon, she continues to drive financial discipline and value creation, positioning the company for long-term success in advancing precision neurology medicines.